Literature DB >> 3466178

Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.

J A Drebin, V C Link, R A Weinberg, M I Greene.   

Abstract

The neu oncogene encodes a 185-kDa transmembrane glycoprotein tumor antigen, termed p185. We have recently described a monoclonal antibody reactive with a cell surface domain of the p185 molecule. In vivo treatment with this anti-p185 monoclonal antibody was able to significantly inhibit the tumorigenic growth of neu-transformed NIH 3T3 cells implanted into nude mice. Such treatment had no effect on the tumorigenic growth of Ha-ras-transformed NIH 3T3 cells. Furthermore, anti-p185 antibody treatment was able to inhibit the growth of the rat neuroblastoma cells from which the neu oncogene was initially isolated. These results demonstrate that a monoclonal antibody reactive with the extracellular domain of an oncogene-encoded protein can exert a significant antitumor effect; such antibodies may prove useful in the therapy of certain malignancies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3466178      PMCID: PMC387088          DOI: 10.1073/pnas.83.23.9129

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line.

Authors:  S Fukushige; K Matsubara; M Yoshida; M Sasaki; T Suzuki; K Semba; K Toyoshima; T Yamamoto
Journal:  Mol Cell Biol       Date:  1986-03       Impact factor: 4.272

3.  Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody.

Authors:  R A Miller; R Levy
Journal:  Lancet       Date:  1981-08-01       Impact factor: 79.321

4.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

Authors:  R A Miller; D G Maloney; R Warnke; R Levy
Journal:  N Engl J Med       Date:  1982-03-04       Impact factor: 91.245

5.  Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells.

Authors:  I S Trowbridge; D L Domingo
Journal:  Nature       Date:  1981-11-12       Impact factor: 49.962

6.  Identification and characterization of the avian erythroblastosis virus erbB gene product as a membrane glycoprotein.

Authors:  M J Hayman; G M Ramsay; K Savin; G Kitchener; T Graf; H Beug
Journal:  Cell       Date:  1983-02       Impact factor: 41.582

7.  Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours.

Authors:  H F Sears; B Atkinson; J Mattis; C Ernst; D Herlyn; Z Steplewski; P Häyry; H Koprowski
Journal:  Lancet       Date:  1982-04-03       Impact factor: 79.321

8.  Regulation of the immune response to tumor antigen.

Authors:  M I Greene; L L Perry; B Benacerraf
Journal:  Am J Pathol       Date:  1979-04       Impact factor: 4.307

9.  Cellular transforming genes.

Authors:  G M Cooper
Journal:  Science       Date:  1982-08-27       Impact factor: 47.728

10.  Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen.

Authors:  I D Bernstein; M R Tam; R C Nowinski
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

View more
  51 in total

Review 1.  The ErbB receptors as targets for breast cancer therapy.

Authors:  J Albanell; J Baselga
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 2.  ErbB receptors: from oncogenes to targeted cancer therapies.

Authors:  Hongtao Zhang; Alan Berezov; Qiang Wang; Geng Zhang; Jeffrey Drebin; Ramachandran Murali; Mark I Greene
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

3.  Antisense-fos RNA causes partial reversion of the transformed phenotypes induced by the c-Ha-ras oncogene.

Authors:  B J Ledwith; S Manam; A R Kraynak; W W Nichols; M O Bradley
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

Review 4.  The legacy of the Philadelphia chromosome.

Authors:  Gary A Koretzky
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

5.  Crystallization and preliminary crystallographic studies of the single-chain variable fragment of antibody chA21 in complex with an N-terminal fragment of ErbB2.

Authors:  Yang Liu; Huihao Zhou; Juanjuan Zhu; Yongxiang Gao; Liwen Niu; Jing Liu; Maikun Teng
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-06-27

6.  Analysis of c-erbB2 protein content of human glioma cells and tumor tissue.

Authors:  H H Engelhard; M Wolters; P S Criswell
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator.

Authors:  Shinichi Asada; Yongmun Choi; Masaki Yamada; Shao-Chun Wang; Mien-Chie Hung; Jun Qin; Motonari Uesugi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

Review 8.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Adaptive Immune Responses and HER2/neu Positive Breast Cancer.

Authors:  Eric D Mortenson; Yang-Xin Fu
Journal:  Curr Pathobiol Rep       Date:  2013-03

Review 10.  Genetic alterations in primary breast cancer.

Authors:  R Callahan
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.